Antisecretory Factor Glioblastoma Phase 2

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

NCT Number	NCT05669820
Lead Sponsor	Peter Siesjö Collaborators: Lund University
Conditions	Glioblastoma
Enrollment	300 participants
Start Date	2024-01-15
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-09